HTA and Reimbursement Submissions

The reimbursement environment is constantly changing. Requirements vary between markets and need coordination across multiple areas to produce high-quality results. To help you achieve market access, our experts across our health economics and market access and outcomes strategy teams have experience contributing to successful submissions in many countries and across therapeutic areas. Our integrated team approach can help you achieve the best result for your product.

We can support you in any aspects of research and product development you require for your reimbursement submissions.

Our experience includes:

Our track record of successfully supporting submissions in major markets includes the following:

  • Australia:  PBAC 
  • Canada: CADTH, INESSS
  • Denmark: DMC, Amgros, DMA
  • Finland: Fimea, Hila
  • Germany: AMNOG
  • Norway: NoMa
  • Republic of Ireland:  NCPE
  • Sweden: TLV
  • United Kingdom: NICE, SMC, AWMSG

In addition to global HTA submissions, we routinely perform the full package of research underpinning AMCP dossiers and preparation for ICER engagements to support launches in the US.


Recent Publications

Aronsson MLing CStevenson ABrodtkorb THSubmission process and requirements of Nordic health technology assessment (HTA) authorities for hospital drugs - implications for market access strategy. Poster to be given at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Heyes AMillar LEarly dialogue with NICE and EUnetHTA: a UK perspective in a politically uncertain era. Poster to be given at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).